# A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B

> **NCT00436163** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 39 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT00436163
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436163, "A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00436163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*